• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于鉴定低级别胶质瘤的诊断和预后标志物的方法。

An approach to the identification of diagnostic and prognostic markers in low-grade gliomas.

机构信息

Izmir Biomedicine and Genome Center, Izmir, Turkey.

Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, Izmir, Turkey.

出版信息

PeerJ. 2023 Mar 16;11:e15096. doi: 10.7717/peerj.15096. eCollection 2023.

DOI:10.7717/peerj.15096
PMID:36945359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10024901/
Abstract

Low-grade gliomas (LGG) are central nervous system Grade I tumors, and as they progress they are becoming one of the deadliest brain tumors. There is still great need for timely and accurate diagnosis and prognosis of LGG. Herein, we aimed to identify diagnostic and prognostic biomarkers associated with LGG, by employing diverse computational approaches. For this purpose, differential gene expression analysis on high-throughput transcriptomics data of LGG corresponding healthy brain tissue, derived from TCGA and GTEx, respectively, was performed. Weighted gene co-expression network analysis of the detected differentially expressed genes was carried out in order to identify modules of co-expressed genes significantly correlated with LGG clinical traits. The genes comprising these modules were further used to construct gene co-expression and protein-protein interaction networks. Based on the network analyses, we derived a consensus of eighteen hub genes, namely, , and . All detected hub genes were up-regulated in LGG, and were also associated with unfavorable prognosis in LGG patients. The findings of this study could be applicable in the clinical setting for diagnosing and monitoring LGG.

摘要

低级别胶质瘤(LGG)是中枢神经系统 I 级肿瘤,随着其发展,它已成为最致命的脑肿瘤之一。因此,仍非常需要及时、准确地诊断和预测 LGG。为此,我们采用多种计算方法,旨在鉴定与 LGG 相关的诊断和预后生物标志物。为此,分别对来自 TCGA 和 GTEx 的 LGG 相应正常脑组织的高通量转录组学数据进行差异基因表达分析。为了鉴定与 LGG 临床特征显著相关的共表达基因模块,对检测到的差异表达基因进行加权基因共表达网络分析。包含这些模块的基因进一步用于构建基因共表达和蛋白质-蛋白质相互作用网络。基于网络分析,我们得出了十八个关键基因的共识,即 、 和 。所有检测到的关键基因在 LGG 中均上调,并且与 LGG 患者的不良预后相关。本研究的结果可适用于临床诊断和监测 LGG。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/13eb3ee8ae17/peerj-11-15096-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/d0ce313806bb/peerj-11-15096-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/d2df624ad377/peerj-11-15096-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/03b26eb0cfa5/peerj-11-15096-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/b50a86f3c550/peerj-11-15096-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/84395d2afeed/peerj-11-15096-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/b3aba3aff344/peerj-11-15096-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/13eb3ee8ae17/peerj-11-15096-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/d0ce313806bb/peerj-11-15096-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/d2df624ad377/peerj-11-15096-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/03b26eb0cfa5/peerj-11-15096-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/b50a86f3c550/peerj-11-15096-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/84395d2afeed/peerj-11-15096-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/b3aba3aff344/peerj-11-15096-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cef3/10024901/13eb3ee8ae17/peerj-11-15096-g007.jpg

相似文献

1
An approach to the identification of diagnostic and prognostic markers in low-grade gliomas.一种用于鉴定低级别胶质瘤的诊断和预后标志物的方法。
PeerJ. 2023 Mar 16;11:e15096. doi: 10.7717/peerj.15096. eCollection 2023.
2
Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.TYROBP 表达升高预示低级别胶质瘤患者预后不良和肿瘤免疫浸润程度高。
BMC Cancer. 2021 Jun 23;21(1):723. doi: 10.1186/s12885-021-08456-6.
3
Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.脑低级别胶质瘤中 C3 的生物信息学分析作为潜在的治疗靶点和促进免疫细胞浸润。
Med Oncol. 2022 Jan 11;39(2):27. doi: 10.1007/s12032-022-01647-6.
4
Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.丝氨酸掺入因子 2(SERINC2)表达预测低级别胶质瘤(LGG)的不良预后:来自生物信息学分析的证据。
J Mol Neurosci. 2020 Oct;70(10):1521-1532. doi: 10.1007/s12031-020-01620-w. Epub 2020 Jul 8.
5
The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.低级别胶质瘤中有前途的新型生物标志物和候选小分子药物:高通量数据的生物信息学分析证据。
J Cell Biochem. 2019 Sep;120(9):15106-15118. doi: 10.1002/jcb.28773. Epub 2019 Apr 24.
6
SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.SHOX2是预测世界卫生组织II-III级弥漫性胶质瘤患者生存的有效独立生物标志物。
EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28.
7
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.CKS2(CDC28 蛋白激酶调节亚基 2)是低级别胶质瘤的预后生物标志物:基于生物信息学分析和免疫组织化学的研究。
Bioengineered. 2021 Dec;12(1):5996-6009. doi: 10.1080/21655979.2021.1972197.
8
Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.神经调节蛋白家族成员相关肿瘤微环境的综合分析预测胶质瘤的预后。
Front Immunol. 2021 May 13;12:682415. doi: 10.3389/fimmu.2021.682415. eCollection 2021.
9
Identification and clinical validation of diverse cell-death patterns-associated prognostic features among low-grade gliomas.识别和临床验证低级别胶质瘤中不同细胞死亡模式相关的预后特征。
Sci Rep. 2024 May 24;14(1):11874. doi: 10.1038/s41598-024-62869-4.
10
Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.低级别胶质瘤中与复发和恶性进展相关的生物标志物及其在免疫治疗中的作用。
Front Immunol. 2022 May 23;13:899710. doi: 10.3389/fimmu.2022.899710. eCollection 2022.

引用本文的文献

1
The role and therapeutic value of NUSAP1 in human cancers.NUSAP1在人类癌症中的作用及治疗价值。
J Transl Med. 2025 Jul 2;23(1):725. doi: 10.1186/s12967-025-06746-2.
2
Development and experimental validation of dephosphorylation-related biomarkers to assess prognosis and immunotherapeutic response in gliomas.用于评估胶质瘤预后和免疫治疗反应的去磷酸化相关生物标志物的开发与实验验证
Front Immunol. 2025 Jan 3;15:1488894. doi: 10.3389/fimmu.2024.1488894. eCollection 2024.
3
N7-methyladenosine-induced SLC7A7 serves as a prognostic biomarker in pan-cancer and promotes CRC progression in colorectal cancer.

本文引用的文献

1
Identification of novel prognostic targets in glioblastoma using bioinformatics analysis.基于生物信息学分析鉴定胶质母细胞瘤的新型预后靶点。
Biomed Eng Online. 2022 Apr 18;21(1):26. doi: 10.1186/s12938-022-00995-8.
2
Screening and Identification of Key Biomarkers in Lower Grade Glioma via Bioinformatical Analysis.通过生物信息学分析筛选和鉴定低级别胶质瘤中的关键生物标志物
Appl Bionics Biomech. 2022 Jan 7;2022:6959237. doi: 10.1155/2022/6959237. eCollection 2022.
3
Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed Glioblastoma.
N7-甲基腺苷诱导的SLC7A7作为泛癌的预后生物标志物,并促进结直肠癌中的结直肠癌进展。
Sci Rep. 2024 Dec 28;14(1):30755. doi: 10.1038/s41598-024-80885-2.
4
Eg5 and Diseases: From the Well-Known Role in Cancer to the Less-Known Activity in Noncancerous Pathological Conditions.驱动蛋白样蛋白5(Eg5)与疾病:从其在癌症中的广为人知的作用到在非癌性病理状况下鲜为人知的活性
Biochem Res Int. 2024 Jun 20;2024:3649912. doi: 10.1155/2024/3649912. eCollection 2024.
5
A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.一种新型过氧化物酶体相关基因特征可预测低级别胶质瘤的临床预后,并与免疫微环境相关。
PeerJ. 2024 Feb 20;12:e16874. doi: 10.7717/peerj.16874. eCollection 2024.
CD80 和 CD86 在新诊断的胶质母细胞瘤肿瘤微环境中的表达及其预后价值。
Can J Neurol Sci. 2023 Mar;50(2):234-242. doi: 10.1017/cjn.2022.5. Epub 2022 Jan 13.
4
Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy.基于代谢特征的亚型可能为低级别胶质瘤的预后和治疗开辟新途径。
Front Cell Dev Biol. 2021 Nov 23;9:755776. doi: 10.3389/fcell.2021.755776. eCollection 2021.
5
CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas.CD74与胶质瘤中的恶性肿瘤及免疫微环境相关。
Front Mol Biosci. 2021 Sep 1;8:706949. doi: 10.3389/fmolb.2021.706949. eCollection 2021.
6
Aberrant nuclear lamina contributes to the malignancy of human gliomas.核纤层结构异常与人类脑胶质瘤的恶性表型相关。
J Genet Genomics. 2022 Feb;49(2):132-144. doi: 10.1016/j.jgg.2021.08.013. Epub 2021 Sep 13.
7
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.ITGB2 作为胶质瘤免疫治疗的预后指标和预测标志物。
Cancer Immunol Immunother. 2022 Mar;71(3):645-660. doi: 10.1007/s00262-021-03022-2. Epub 2021 Jul 27.
8
Molecular and Circulating Biomarkers of Brain Tumors.脑肿瘤的分子和循环生物标志物。
Int J Mol Sci. 2021 Jun 29;22(13):7039. doi: 10.3390/ijms22137039.
9
Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.TYROBP 表达升高预示低级别胶质瘤患者预后不良和肿瘤免疫浸润程度高。
BMC Cancer. 2021 Jun 23;21(1):723. doi: 10.1186/s12885-021-08456-6.
10
GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA.GEPIA2021:将多种基于去卷积的分析整合到 GEPIA 中。
Nucleic Acids Res. 2021 Jul 2;49(W1):W242-W246. doi: 10.1093/nar/gkab418.